RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
RetinalGenix Technologies (OTCQB:RTGN) has secured a laboratory lease agreement with MBC BioLabs in San Carlos, California. The agreement includes a potential investment option from Mission BioCapital, MBC Biolabs' affiliate. The facility will be used to advance the company's DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform and research on repurposing existing drugs for dementia, parkinsonism, and macular degeneration.
The fully equipped laboratory provides access to advanced scientific equipment and is strategically located near Charles River Laboratories' vivarium facility. Dr. Fred Chasalow, Special Consultant for Therapeutics, will lead the laboratory activities. The company is also in discussions for potential collaboration with Dr. Anatoly Dritschilo of Shuttle Pharmaceuticals and plans to expand IRB approval for clinical studies across multiple practices.
RetinalGenix Technologies (OTCQB:RTGN) ha stipulato un contratto di locazione per un laboratorio con MBC BioLabs a San Carlos, California. L'accordo prevede una possibile opzione di investimento da parte di Mission BioCapital, affiliata di MBC BioLabs. La struttura sarà utilizzata per sviluppare la piattaforma DNA/RNA/GPS Pharmaco-Genetic Mapping™ dell'azienda e per la ricerca sul riutilizzo di farmaci esistenti per demenza, parkinsonismo e degenerazione maculare.
Il laboratorio, completamente attrezzato, offre accesso a apparecchiature scientifiche avanzate ed è situato strategicamente vicino al vivarium di Charles River Laboratories. Il Dr. Fred Chasalow, consulente speciale per le terapie, guiderà le attività del laboratorio. L'azienda sta anche valutando una possibile collaborazione con il Dr. Anatoly Dritschilo di Shuttle Pharmaceuticals e pianifica di estendere l'approvazione IRB per studi clinici in più strutture.
RetinalGenix Technologies (OTCQB:RTGN) ha asegurado un contrato de arrendamiento de laboratorio con MBC BioLabs en San Carlos, California. El acuerdo incluye una opción de inversión potencial por parte de Mission BioCapital, afiliada de MBC BioLabs. La instalación se utilizará para avanzar en la plataforma DNA/RNA/GPS Pharmaco-Genetic Mapping™ de la empresa y en la investigación sobre la reutilización de medicamentos existentes para la demencia, el parkinsonismo y la degeneración macular.
El laboratorio completamente equipado ofrece acceso a equipos científicos avanzados y está estratégicamente ubicado cerca de la instalación vivarium de Charles River Laboratories. El Dr. Fred Chasalow, Consultor Especial en Terapéutica, dirigirá las actividades del laboratorio. La empresa también está en conversaciones para una posible colaboración con el Dr. Anatoly Dritschilo de Shuttle Pharmaceuticals y planea ampliar la aprobación IRB para estudios clínicos en múltiples prácticas.
RetinalGenix Technologies (OTCQB:RTGN)는 캘리포니아 산카를로스에 위치한 MBC BioLabs와 실험실 임대 계약을 체결했습니다. 이 계약에는 MBC BioLabs의 계열사인 Mission BioCapital의 잠재적 투자 옵션도 포함되어 있습니다. 이 시설은 회사의 DNA/RNA/GPS Pharmaco-Genetic Mapping™ 플랫폼 개발과 치매, 파킨슨증, 황반변성에 대한 기존 약물 재활용 연구에 사용될 예정입니다.
완비된 실험실은 첨단 과학 장비에 접근할 수 있으며 Charles River Laboratories의 비바리움 시설 근처에 전략적으로 위치해 있습니다. 프레드 차살로우 박사가 치료 분야 특별 고문으로서 실험실 활동을 이끌 예정입니다. 회사는 또한 아나톨리 드리치로 박사와의 잠재적 협력을 논의 중이며, 여러 기관에서 임상 연구를 위한 IRB 승인을 확대할 계획입니다.
RetinalGenix Technologies (OTCQB:RTGN) a conclu un contrat de location de laboratoire avec MBC BioLabs à San Carlos, Californie. L'accord comprend une option d'investissement potentielle de Mission BioCapital, affiliée à MBC BioLabs. L'installation sera utilisée pour faire progresser la plateforme DNA/RNA/GPS Pharmaco-Genetic Mapping™ de l'entreprise et pour la recherche sur la réutilisation de médicaments existants pour la démence, le parkinsonisme et la dégénérescence maculaire.
Le laboratoire entièrement équipé offre un accès à des équipements scientifiques avancés et est stratégiquement situé près de l'installation vivarium de Charles River Laboratories. Le Dr Fred Chasalow, consultant spécial en thérapeutique, dirigera les activités du laboratoire. L'entreprise est également en discussions pour une collaboration potentielle avec le Dr Anatoly Dritschilo de Shuttle Pharmaceuticals et prévoit d'étendre l'approbation IRB pour des études cliniques dans plusieurs établissements.
RetinalGenix Technologies (OTCQB:RTGN) hat einen Labor-Mietvertrag mit MBC BioLabs in San Carlos, Kalifornien, abgeschlossen. Der Vertrag beinhaltet eine mögliche Investitionsoption von Mission BioCapital, einer Tochtergesellschaft von MBC BioLabs. Die Einrichtung wird genutzt, um die DNA/RNA/GPS Pharmaco-Genetic Mapping™ Plattform des Unternehmens voranzutreiben und Forschungen zur Wiederverwendung bestehender Medikamente bei Demenz, Parkinsonismus und Makuladegeneration durchzuführen.
Das voll ausgestattete Labor bietet Zugang zu fortschrittlichen wissenschaftlichen Geräten und befindet sich strategisch in der Nähe der Vivarium-Einrichtung von Charles River Laboratories. Dr. Fred Chasalow, Spezialberater für Therapeutika, wird die Laboraktivitäten leiten. Das Unternehmen befindet sich außerdem in Gesprächen über eine mögliche Zusammenarbeit mit Dr. Anatoly Dritschilo von Shuttle Pharmaceuticals und plant, die IRB-Zulassung für klinische Studien auf mehrere Einrichtungen auszudehnen.
- Access to world-class scientific equipment and facilities through MBC BioLabs lease
- Potential investment opportunity from Mission BioCapital
- Strategic location near Charles River Laboratories vivarium facility for animal research
- Potential collaboration with Dr. Anatoly Dritschilo of Shuttle Pharmaceuticals
- Current CDMRP grant funding for novel neurohormone research
- None.
Company to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseases
APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California. The lease includes an option for Mission BioCapital, an affiliate of MBC Biolabs, to potentially invest in RetinalGenix. The Company plans to use the facility to further the development of its RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform.
The fully equipped laboratory space provides access to world-class scientific equipment, including incubators, centrifuges, freeze dryers, and mass spectrometers. The lab is strategically located close to the Charles River Laboratories vivarium lab facility, which provides turnkey solutions for advancing in vivo animal research studies in which RetinalGenix will likely engage.
In addition to further development of RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, the Company is engaged in research to repurpose previous commercialized drugs for new indications in dementia, parkinsonism and macular degeneration. The Company holds patents for repurposing various legacy therapeutics that were on the market for over 30 years. These drugs are now being re-evaluated and repurposed through advanced genetic profiling.
“We are thrilled to join the prestigious cohort of leading-edge bio companies at MBC Biolabs,” said Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix. “This opportunity will allow us to accelerate our mission to repurpose FDA-approved therapeutics for new indications, and to explore therapies targeting other ocular and neurodegenerative diseases.”
“RetinalGenix intends to expand Institutional Review Board (IRB) approval of a clinical study to include multiple practices. The facility at MBCBiolab is the perfect laboratory to accelerate the development of our RetinalGenix DNA/GPS™ platform,” stated Dr. Larry Perich, director of the current Florida-based study.
The Company is currently discussing a potential collaboration with Dr. Anatoly Dritschilo, the Co-founder, Chairman of the Board, and Chief Science Officer of Shuttle Pharmaceuticals. Dr. Dritschilo is a distinguished clinician-scientist with primary expertise in radiation oncology and molecular radiation biology. His leadership and scientific contributions in the field have been instrumental in advancing therapeutic strategies that integrate molecular and radiation-based approaches to cancer treatment.
Fred Chasalow, Ph.D., Special Consultant for Therapeutics at RetinalGenix will direct the Company’s MBC Biolabs laboratory activities. Among his many accomplishments, Dr. Chasalow is credited with discovering three novel steroids. Fred also serves on the Medical Advisory Board of DNA-GPS™, a division of RetinalGenix. Dr. Chasalow has a current CDMRP grant to investigate novel neurohormones. CDMRP is a DoD program that funds biomedical research in response to the needs of the public, the military, and Congress.
About MBC BioLabs
MBC BioLabs believes startups are the greatest force for positive change in the world. We offer flexible state-of-the-art lab space, facilities, access to millions of dollars in equipment and instrumentation, along with a vibrant community of like-minded individuals tackling some of the world's biggest problems. We are dedicated to helping biotech startups succeed – we enable awesome. We have helped launch and grow over 350 companies since opening in October of 2013, and together, MBC companies have initiated 176 clinical trials, introduced 71 products to market, and raised nearly
About RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. is an innovative ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine.
For more information, visit RetinalGenix Technologies website.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, the Company can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond the Company's control), assumptions and other factors that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results may differ materially from those in the forward-looking statements, and the trading price for the Company's common stock may fluctuate significantly. Forward-looking statements are also affected by the risk factors described in the Company's filings with the SEC. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
(800) 331-5446
IR@retinalgenix.com
FAQ
What is the purpose of RetinalGenix's (RTGN) new laboratory lease with MBC BioLabs?
Who will lead RetinalGenix's (RTGN) laboratory activities at the new MBC BioLabs facility?
What potential investment opportunity is included in RetinalGenix's (RTGN) laboratory lease agreement?
What diseases is RetinalGenix (RTGN) targeting with its drug repurposing research?
Where is RetinalGenix's (RTGN) new laboratory facility located?
